Test Definition: CH8BI

Chromogenic FVIII Inhibitor Interp

Overview

Useful For

Detecting the presence and titer of a specific factor inhibitor directed against coagulation factor VIII

This test is **not useful** for detecting the presence of inhibitors directed against other clotting factors and **will not** detect the presence of lupus anticoagulants.

Method Name

Only orderable as part of a profile. For more information see CH8BP / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

NY State Available

Yes

Specimen

Specimen Type

Plasma Na Cit

Specimen Required

Only orderable as part of a profile. For more information see CH8BP / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

Specimen Minimum Volume

1 mL

Reject Due To

Gross hemolysis	Reject
Gross lipemia	Reject
Gross icterus	Reject
Other	IV heparin contamination

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Plasma Na Cit	Frozen	14 days	

Clinical and Interpretive

Clinical Information

Factor VIII inhibitors are IgG antibodies directed against coagulation FVIII that typically result in development of potentially life-threatening hemorrhage. These antibodies may be alloimmune: developing in patients with congenital FVIII deficiency (hemophilia A) in response to therapeutic infusions of factor VIII concentrate or autoimmune:

occurring in nonhemophiliac patients (not previously factor VIII deficient) either spontaneously, or during pregnancy or in association with autoimmune diseases.

Reference Values

Only orderable as part of a profile. For more information see CH8BP / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

An interpretive report will be provided.

Interpretation

The interpretive report will include assay information, background information, and conclusions based on the test results.

Cautions

Contamination with excess heparin and hemo-dilution due to improper specimen collection through an intravenous access device or collection above a running intravenous fluid line may cause spurious results.

Clinical Reference

1. Peyvandi F, Oldenburg J, Friedman KD: A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 2016 Feb;14(2):248-261

2. Verbruggen B, van Heerde WL, Laros-van Gorkom BA: Improvements in Factor VIII Inhibitor Detection: From Bethesda to Nijmegen. Semin Thromb Hemost 2009 Nov;35(8):752-759

3. Miller C, Platt S, Rice A, et al: Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012;10:1055-1061

Performance

Method Description

A coagulation expert (clinician or hematopathologist) reviews the laboratory data and an interpretive report is issued.(Unpublished Mayo method)

PDF Report

No

Day(s) and Time(s) Test Performed

Monday through Friday; Varies

Analytic Time

2 days

Specimen Retention Time

7 days

Performing Laboratory Location

Rochester

Fees and Codes

Fees

- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification

Not Applicable

CPT Code Information

85390

LOINC® Information

Test ID	Test Order Name	Order LOINC Value
CH8BI	Chromogenic FVIII Inhibitor Interp	95122-8

Result ID	Test Result Name	Result LOINC Value
606844	Chromogenic FVIII Inhibitor Interp	95122-8
606865	Reviewed by	18771-6